GlassScriptPhysician profile
Danny Keith Carroll
NPI 1639172760
$391.89
in general payments reported to CMS, 2019-2025
11 companies · $123 in 2025
The $123 reported for 2025 was less than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $116 · 2021: $12.36 · 2022: $18.03 · 2023: $44.92 · 2024: $77.66 · 2025: $123.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $246.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $245.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $133.97 | 2020-2025 | Variax, Gamma, Axsos |
| Medical Device Business Services, INC. | $47.46 | 2025 | Velys |
| Exactech, INC. | $46.79 | 2020 | |
| Medtronic, INC. | $27.65 | 2023 | Nexpowder |
| Takeda Pharmaceuticals U.S.A., INC. | $22.17 | 2024 | Entyvio |
| Ardelyx, INC. | $21.33 | 2024 | Ibsrela |
| Wright Medical Technology, INC. | $19.85 | 2020 | |
| Janssen Biotech, INC. | $19.61 | 2025 | Tremfya |
| Depuy Synthes Sales INC. | $18.03 | 2022 | |
| Heron Therapeutics, INC. | $17.76 | 2024 | Aponvie |
| Kerecis Limited | $17.27 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danny Carroll listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.